…
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -24.07M | -30.91M | -24.64M | -30.77M | -11.84M |
| Net income | -20.32M | -29.56M | -15.38M | -35.91M | -13.34M |
| Selling general administrative | 9.84M | 10.81M | 8.76M | 6.93M | 6.56M |
| Gross profit | - | - | - | - | 0.00M |
| Reconciled depreciation | 1.96M | 1.96M | 1.95M | 1.96M | 1.96M |
| Ebit | -24.40M | -31.53M | -36.29M | -23.49M | -17.65M |
| Ebitda | -25.85M | -31.54M | -39.25M | -15.94M | -15.68M |
| Depreciation and amortization | -1.45M | -0.01M | -2.96M | 7.54M | 1.96M |
| Non operating income net other | - | - | 11.65M | -7.29M | 2.46M |
| Operating income | -24.40M | -31.53M | -36.29M | -23.49M | -14.30M |
| Other operating expenses | 25.11M | 32.26M | 31.95M | 23.20M | 13.73M |
| Interest expense | -0.33M | 0.62M | 0.00M | 0.00M | 0.06M |
| Tax provision | - | - | - | - | 0.00M |
| Interest income | 0.30M | 0.11M | - | 0.48M | - |
| Net interest income | 0.30M | 0.11M | 0.01M | 0.15M | -0.06M |
| Extraordinary items | - | - | - | - | -1.49M |
| Income tax expense | -3.75M | -1.35M | -9.26M | 5.14M | 2.52M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 25.11M | 32.26M | 31.95M | 23.20M | 13.73M |
| Cost of revenue | - | - | - | - | 0.00M |
| Total other income expense net | 0.33M | 0.62M | 11.65M | -7.29M | 1.96M |
| Discontinued operations | - | - | - | - | -1.49M |
| Net income from continuing ops | -24.07M | -30.91M | -24.64M | -30.77M | -11.84M |
| Net income applicable to common shares | -24.07M | -30.91M | -24.64M | -30.77M | -13.34M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 180.69M | 26.50M | 35.55M | 64.98M | 38.17M |
| Intangible assets | 8.75M | 10.69M | 12.64M | 14.58M | 16.52M |
| Other current assets | 1.68M | 1.04M | 1.12M | 1.02M | 0.41M |
| Total liab | 23.18M | 16.15M | 17.76M | 19.43M | 23.23M |
| Total stockholder equity | 157.51M | 10.35M | 17.79M | 45.55M | 14.95M |
| Deferred long term liab | - | - | - | 0.54M | 12.18M |
| Other current liab | 8.08M | 5.38M | 0.32M | 0.20M | 0.38M |
| Common stock | 0.03M | 0.01M | 0.08M | 0.08M | 0.04M |
| Capital stock | 0.03M | 0.01M | 0.08M | 0.08M | 0.04M |
| Retained earnings | -276.41M | -237.42M | -213.35M | -182.44M | -157.81M |
| Other liab | - | 8.84M | 9.58M | 10.82M | 18.11M |
| Other assets | 0.00M | - | 0.04M | 0.14M | 0.06M |
| Cash | 169.68M | 14.60M | 21.30M | 49.22M | 20.73M |
| Total current liabilities | 11.51M | 7.31M | 8.01M | 8.62M | 4.96M |
| Current deferred revenue | - | - | 4.15M | 4.79M | 2.28M |
| Net debt | -169.28M | -14.45M | -20.85M | -49.09M | -20.43M |
| Short term debt | 0.27M | 0.15M | 0.28M | 0.14M | 0.30M |
| Short long term debt total | 0.40M | 0.15M | 0.46M | 0.14M | 0.30M |
| Other stockholder equity | 433.88M | 247.76M | 231.07M | 227.91M | 172.71M |
| Property plant equipment | - | 0.16M | 0.45M | 0.02M | 0.02M |
| Total current assets | 171.36M | 15.65M | 22.42M | 50.24M | 21.14M |
| Net tangible assets | - | -0.34M | 5.16M | 30.97M | -1.58M |
| Short term investments | - | - | - | - | 0.00M |
| Accounts payable | 3.15M | 1.78M | 3.25M | 3.49M | 2.00M |
| Accumulated other comprehensive income | 0.00M | - | - | - | -0.03M |
| Common stock total equity | - | - | - | 0.08M | 0.04M |
| Retained earnings total equity | - | - | - | -182.44M | -157.81M |
| Non currrent assets other | 0.16M | - | 0.04M | 0.14M | 0.06M |
| Non current assets total | 9.33M | 10.85M | 13.13M | 14.74M | 17.03M |
| Capital lease obligations | 0.40M | 0.15M | 0.46M | 0.14M | 0.30M |
| Long term debt total | - | - | - | - | 0.01M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.01M | -0.02M | -0.01M | 0.53M | -0.18M |
| Change to liabilities | -1.48M | -0.23M | 2.04M | 1.11M | 0.21M |
| Total cashflows from investing activities | -0.01M | -0.02M | -0.01M | 0.53M | -0.18M |
| Net borrowings | - | -0.01M | -0.02M | -0.00M | -0.00M |
| Total cash from financing activities | 14.09M | -0.13M | 53.72M | 14.48M | 17.83M |
| Change to operating activities | 0.72M | -0.91M | 1.48M | 1.44M | -0.17M |
| Net income | -24.07M | -30.91M | -24.64M | -30.77M | -11.84M |
| Change in cash | -6.70M | -27.92M | 28.49M | -2.37M | 5.96M |
| Begin period cash flow | 21.30M | 49.22M | 20.73M | 23.10M | 17.14M |
| End period cash flow | 14.60M | 21.30M | 49.22M | 20.73M | 23.10M |
| Total cash from operating activities | -20.78M | -27.77M | -25.22M | -17.38M | -11.68M |
| Issuance of capital stock | 15.15M | 0.00M | 53.72M | 14.48M | 16.50M |
| Depreciation | 1.96M | 1.96M | 1.95M | 1.96M | 1.96M |
| Other cashflows from investing activities | - | - | - | 0.55M | -0.17M |
| Sale purchase of stock | - | - | 0.02M | 14.48M | 16.50M |
| Other cashflows from financing activities | -1.06M | -0.12M | 0.02M | 0.53M | 1.33M |
| Change to netincome | 2.08M | 2.33M | -10.14M | 8.27M | -2.45M |
| Capital expenditures | 0.01M | 0.02M | 0.01M | 0.02M | 0.01M |
| Change receivables | - | - | - | 0.06M | -0.06M |
| Cash flows other operating | - | - | 5.56M | -28.77M | -11.33M |
| Cash and cash equivalents changes | - | - | 28.49M | -2.37M | 5.96M |
| Change in working capital | -0.76M | -1.15M | 2.98M | 2.50M | 0.08M |
| Stock based compensation | 2.53M | 3.28M | 1.50M | 0.82M | 0.99M |
| Other non cash items | -0.45M | -0.44M | 4.62M | 1.15M | 1.00M |
| Free cash flow | -20.79M | -27.79M | -25.23M | -17.40M | -11.69M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
203 Redwood Shores Parkway, Redwood City, CA, United States, 94065
650 213 8444
33
| Name | Title | Year Born |
|---|---|---|
| Dr. Anish Bhatnagar M.D. | Pres, CEO, COO & Director | 1970 |
| Mr. James H. MacKaness | Chief Financial Officer | 1964 |
| Ms. Kristen Yen M.S. | VP of Clinical Operations | 1969 |
| Ms. Patricia C. Hirano | VP of Regulatory Affairs | 1966 |
| Mr. Anthony Wondka | Sr. VP & GM | 1962 |
| Dr. Neil M. Cowen M.B.A., Ph.D., MBA | Sr. VP of Drug Devel. | NA |
| Dr. Anish Bhatnagar M.D. | President, CEO, COO & Director | 1970 |
| Ms. Patricia C. Hirano | Vice President of Regulatory Affairs | 1966 |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of Drug Development | NA |
| Ms. Meredith Manning M.B.A. | Chief Commercial Officer | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.